Yiqi Huoxue Tongluo decoction combined with conventional medicine therapy: effects on restenosis rates and clinical efficacy in patients with coronary heart disease undergoing percutaneous coronary intervention.
{"title":"Yiqi Huoxue Tongluo decoction combined with conventional medicine therapy: effects on restenosis rates and clinical efficacy in patients with coronary heart disease undergoing percutaneous coronary intervention.","authors":"Xing Zhao, Lihua Zhang, Zhijie Liu","doi":"10.3389/fcvm.2025.1600189","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to investigate the effect of Yiqi Huoxue Tongluo decoction (YHTD) in combination with conventional medicine therapy on restenosis rates and clinical efficacy in patients with coronary heart disease undergoing percutaneous coronary intervention.</p><p><strong>Methods: </strong>A total of 80 patients with coronary artery disease who underwent PCI between August 2019 and February 2021 were selected, and the patients were assigned to either the control group (<i>n</i> = 40) or the observation group (<i>n</i> = 40) according to a randomized numerical table. The control group received conventional medicine treatment, while the observation group took YHTD alongside conventional medicine treatment. Coronary angiography was performed after 6 months of treatment to compare the changes in coronary restenosis, TCM syndrome scores, Seattle Angina Questionnaire (SAQ) scores, cardiac function indexes, and related serum biomarkers between the two groups.</p><p><strong>Results: </strong>After treatment, the TCM syndrome scores of patients in both groups were lower than those before treatment, and the post-treatment TCM syndrome scores of the observation group were significantly lower than those of the control group. Similarly, the SAQ scores of patients in both groups were significantly higher than those before treatment, and the SAQ scores of the observation group were significantly higher than those of the control group. After treatment, both groups showed significant reductions in the LVEDD and LVESD compared with those before treatment, and the LVEDD and LVESD values of the observation group were significantly lower than those of the control group. Similarly, the LVEF and SV of patients in both groups increased compared with those before treatment; however, the LVEF and SV values of the observation group were significantly higher than those of the control group, and the difference was statistically significant. After treatment, hs-CRP, Hcy, and sST2 were significantly reduced in both groups, and the levels of hs-CRP, Hcy, and sST2 in the observation group were significantly lower than those in the control group.</p><p><strong>Conclusion: </strong>YHTD combined with conventional medicine therapy can significantly reduce the rate of coronary restenosis in post-PCI patients, improve the TCM symptoms, alleviate angina symptoms, enhance cardiac function indexes, and effectively regulate serum biomarker levels, which offers a better choice for the treatment of post-PCI coronary artery disease.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1600189"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12498481/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1600189","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aims to investigate the effect of Yiqi Huoxue Tongluo decoction (YHTD) in combination with conventional medicine therapy on restenosis rates and clinical efficacy in patients with coronary heart disease undergoing percutaneous coronary intervention.
Methods: A total of 80 patients with coronary artery disease who underwent PCI between August 2019 and February 2021 were selected, and the patients were assigned to either the control group (n = 40) or the observation group (n = 40) according to a randomized numerical table. The control group received conventional medicine treatment, while the observation group took YHTD alongside conventional medicine treatment. Coronary angiography was performed after 6 months of treatment to compare the changes in coronary restenosis, TCM syndrome scores, Seattle Angina Questionnaire (SAQ) scores, cardiac function indexes, and related serum biomarkers between the two groups.
Results: After treatment, the TCM syndrome scores of patients in both groups were lower than those before treatment, and the post-treatment TCM syndrome scores of the observation group were significantly lower than those of the control group. Similarly, the SAQ scores of patients in both groups were significantly higher than those before treatment, and the SAQ scores of the observation group were significantly higher than those of the control group. After treatment, both groups showed significant reductions in the LVEDD and LVESD compared with those before treatment, and the LVEDD and LVESD values of the observation group were significantly lower than those of the control group. Similarly, the LVEF and SV of patients in both groups increased compared with those before treatment; however, the LVEF and SV values of the observation group were significantly higher than those of the control group, and the difference was statistically significant. After treatment, hs-CRP, Hcy, and sST2 were significantly reduced in both groups, and the levels of hs-CRP, Hcy, and sST2 in the observation group were significantly lower than those in the control group.
Conclusion: YHTD combined with conventional medicine therapy can significantly reduce the rate of coronary restenosis in post-PCI patients, improve the TCM symptoms, alleviate angina symptoms, enhance cardiac function indexes, and effectively regulate serum biomarker levels, which offers a better choice for the treatment of post-PCI coronary artery disease.
期刊介绍：
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
